Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials.

BACKGROUND Uncertainty persists concerning the effect of improved long-term glycemic control on macrovascular disease in diabetes mellitus (DM). METHODS We performed a systematic review and meta-analysis of randomized controlled trials comparing interventions to improve glycemic control with conventional treatment in type 1 and type 2 diabetes. Outcomes included the incidence rate ratios for any macrovascular event, cardiac events, stroke, and peripheral arterial disease, and the number needed to treat intensively during 10 years to prevent one macrovascular event. RESULTS The analysis was based on 8 randomized comparisons including 1800 patients with type 1 DM (134 macrovascular events, 40 cardiac events, 88 peripheral vascular events, 6 cerebrovascular events, 11293 person-years of follow-up) and 6 comparisons including 4472 patients with type 2 DM (1587 macrovascular events, 1197 cardiac events, 87 peripheral vascular events, 303 cerebrovascular events, 43607 person-years). Combined incidence rate ratios for any macrovascular event were 0.38 (95% CI 0.26-0.56) in type 1 and 0.81 (0.73-0.91) in type 2 DM. In type 1 DM, effect was mainly based on reduction of cardiac and peripheral vascular events and, in type 2 DM, due to reductions in stroke and peripheral vascular events. Effects appear to be particularly important in younger patients with shorter duration of diabetes. CONCLUSIONS Our data suggest that attempts to improve glycemic control reduce the incidence of macrovascular events both in type 1 and type 2 DM. In absolute terms, benefits are comparable, although effects on specific manifestations of macrovascular disease differ.

[1]  Oluf Pedersen,et al.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. , 2003, The New England journal of medicine.

[2]  J Herlitz,et al.  Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. , 1995, Journal of the American College of Cardiology.

[3]  Karen A Robinson,et al.  Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. , 2002, International journal of epidemiology.

[4]  D. Peters,et al.  Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. , 1995, Drugs.

[5]  Neil R. Powe,et al.  Meta-Analysis: Glycosylated Hemoglobin and Cardiovascular Disease in Diabetes Mellitus , 2004, Annals of Internal Medicine.

[6]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[7]  C Cates,et al.  Confidence intervals for the number needed to treat , 1999 .

[8]  P. Reichard,et al.  Mortality and Treatment Side-Effects During Long-Term Intensified Conventional Insulin Treatment in the Stockholm Diabetes Intervention Study , 1994, Diabetes.

[9]  Philip D. Harvey,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.

[10]  J. Baynes.  Role of Oxidative Stress in Development of Complications in Diabetes , 1991, Diabetes.

[11]  E. Feskens,et al.  Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria , 1999, The Lancet.

[12]  Long-term correction of hyperglycemia and progression of retinopathy in insulin dependent diabetes. A five-year randomized prospective study. , 1988, Diabetes research.

[13]  J Herlitz,et al.  Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. , 2005, European heart journal.

[14]  Douglas G Altman,et al.  Systematic reviews in health care: Assessing the quality of controlled clinical trials. , 2001, BMJ.

[15]  S. Sharp,et al.  Explaining heterogeneity in meta-analysis: a comparison of methods. , 1999 .

[16]  Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe. , 1999, Lancet.

[17]  K. J. Polley.  Intervention study , 2007, Calcified Tissue International.

[18]  UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance. , 1991, Diabetologia.

[19]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[20]  P. Libby,et al.  Diabetic macrovascular disease: the glucose paradox? , 2002, Circulation.

[21]  D. Singer,et al.  The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. , 2001, The American journal of medicine.

[22]  J P Vandenbroucke,et al.  Bias in meta-analysis detected by a simple, graphical test , 1998 .

[23]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[24]  Markolf Hanefeld,et al.  Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. , 2003, JAMA.

[25]  Irene M. Stratton,et al.  UK prospective diabetes study (UKPDS) , 2004, Diabetologia.

[26]  Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. , 1995, The American journal of cardiology.

[27]  R. C. Turner,et al.  PREVENTION OF DETERIORATION OF RENAL AND SENSORY-NERVE FUNCTION BY MORE INTENSIVE MANAGEMENT OF INSULIN-DEPENDENT DIABETIC PATIENTS A Two-year Randomised Prospective Study , 1983, The Lancet.

[28]  M. Egger,et al.  Women, older persons, and ethnic minorities: factors associated with their inclusion in randomised trials of statins 1990 to 2001 , 2003, Heart.

[29]  R. Marfella,et al.  Metformin Improves Glucose, Lipid Metabolism, and Reduces Blood Pressure in Hypertensive, Obese Women , 1993, Diabetes Care.

[30]  F. Nuttall,et al.  Cardiovascular Events and Correlates in the Veterans Affairs Diabetes Feasibility Trial Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes , 1997 .

[31]  Darren K Mcguire,et al.  Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events. , 2005, European heart journal.

[32]  R. Nesto.  C‐reactive protein, its role in inflammation, Type 2 diabetes and cardiovascular disease, and the effects of insulin‐sensitizing treatment with thiazolidinediones , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[33]  R. Holman,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. , 1998 .

[34]  T. Deckert,et al.  Prognosis of diabetics with diabetes onset before the age of thirty-one. I. Survival, causes of death, and complications. , 1978, Diabetologia.

[35]  H. Keen,et al.  A prospective study of mortality among middle-aged diabetic patients (the London cohort of the WHO Multinational Study of Vascular Disease in Diabetics) I: causes and death rates , 1990, Diabetologia.

[36]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[37]  S. Haffner,et al.  Hyperglycemia as a cardiovascular risk factor. , 2003, The American journal of medicine.

[38]  M. Brownlee,et al.  Glycation Products and the Pathogenesis of Diabetic Complications , 1992, Diabetes Care.

[39]  B. Feldt-Rasmussen,et al.  Effect of improved metabolic control on loss of kidney function in Type 1 (insulin-dependent) diabetic patients: an update of the Steno studies , 1991, Diabetologia.

[40]  J. Eriksson,et al.  Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes , 2004, Diabetic medicine : a journal of the British Diabetic Association.

[41]  Peter Libby,et al.  Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. , 2002, JAMA.

[42]  M. Shichiri,et al.  Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. , 2000, Diabetes care.

[43]  G. Smith,et al.  Meta-analysis: Potentials and promise , 1997, BMJ.

[44]  P. Glasziou,et al.  Bias in meta-analysis detected by a simple, graphical test. Graphical test is itself biased. , 1998, BMJ.

[45]  B. Zinman,et al.  Effect of intensive therapy on early macrovascular disease in young individuals with type 1 diabetes. A systematic review and meta-analysis. , 1999, Diabetes care.